Abstract
The optimal anticoagulation regimen during catheter-directed thrombolysis (CDT) for deep venous thrombosis (DVT) remains a subject of clinical debate. This retrospective study evaluates the effectiveness and safety of low molecular‑weight heparin (LMWH) as an alternative to traditional unfractionated heparin. Analyzing 61 patients, the study compares therapeutic-dose (TPDA) and sub-therapeutic-dose (sub-TPDA) regimens. Results indicate that LMWH is both effective and safe, with high thrombolysis success rates and minimal complications, regardless of the dosage level.
Introduction
Deep Venous Thrombosis (DVT) presents a significant risk for Post-Thrombotic Syndrome (PTS), a chronic condition characterized by pain and swelling. While standard anticoagulation prevents clot propagation, Catheter-Directed Thrombolysis (CDT) is often employed to actively dissolve the thrombus and preserve venous valve function. A critical challenge in CDT is maintaining adequate anticoagulation to prevent catheter-related thrombosis without inducing major bleeding. While Unfractionated Heparin (UFH) has been the standard, its requirement for continuous monitoring makes Low Molecular-Weight Heparin (LMWH) an attractive, more predictable alternative.
Methods
This study retrospectively reviewed 61 patients (61 limbs) treated for DVT at Sun Yat-sen Memorial Hospital between 2014 and 2019. All patients underwent CDT using urokinase. Patients were categorized into two groups based on their LMWH regimen:
- Therapeutic-Dose Anticoagulation (TPDA): 1 mg/kg LMWH twice daily.
- Sub-Therapeutic-Dose Anticoagulation (sub-TPDA): 40 mg LMWH every 12 hours.
Efficacy was measured by the degree of thrombolysis (complete >90%, partial 50-90%) and clinical improvement in limb circumference. Safety was assessed through the incidence of bleeding complications and pulmonary embolism.
Results
The study population had a median age of 56.2 years, with a balanced gender distribution. Acute DVT was present in 63.9% of cases, while 36.1% were subacute.
Efficacy and Safety
Overall, the treatment was highly successful, with 91.8% of patients achieving complete or partial thrombolysis. Clinical improvement was noted in 93.4% of the cohort. Regarding safety, no major bleeding, symptomatic pulmonary embolism, or deaths occurred. Minor bleeding was observed in 8.2% of cases, which researchers noted was primarily associated with higher urokinase infusion rates rather than the heparin dose.
Dose Comparison
Statistical analysis revealed no significant differences between the TPDA and sub-TPDA groups in terms of thrombolysis success (p = 0.665) or minor bleeding rates (p = 0.641). This suggests that a lower, sub-therapeutic dose of LMWH may provide sufficient anticoagulation during the CDT procedure without increasing the risk of hemorrhage.
Discussion
The findings support the transition from intravenous UFH to subcutaneous LMWH during CDT. LMWH offers a more predictable pharmacological profile and simplifies patient management. The lack of significant difference between therapeutic and sub-therapeutic dosing suggests a "less is more" approach may be viable, potentially reducing the overall risk profile of the procedure without sacrificing efficacy. Even in subacute cases, which are traditionally harder to treat, the combined success rate remained high.
Conclusion
Anticoagulation using LMWH during CDT for DVT is both effective and safe. Sub-therapeutic dosing appears to be as effective as full therapeutic dosing, achieving high rates of thrombus resolution with a low risk of complications. Future prospective, randomized trials are needed to confirm these findings and refine optimal dosing protocols.
Summary updated